Poseida Therapeutics (NASDAQ:PSTX) Receives “Market Perform” Rating from William Blair

William Blair reissued their market perform rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report published on Tuesday morning,Benzinga reports.

Separately, HC Wainwright restated a “neutral” rating and set a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday.

Poseida Therapeutics Trading Up 228.0 %

Poseida Therapeutics stock opened at $9.38 on Tuesday. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $9.41. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The business has a 50 day moving average price of $2.90 and a two-hundred day moving average price of $2.97. The stock has a market cap of $914.17 million, a price-to-earnings ratio of -14.89 and a beta of 0.54.

Hedge Funds Weigh In On Poseida Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP acquired a new stake in Poseida Therapeutics during the second quarter worth approximately $31,000. Bayesian Capital Management LP acquired a new stake in Poseida Therapeutics during the first quarter worth approximately $33,000. Rothschild Investment LLC acquired a new stake in Poseida Therapeutics during the second quarter worth approximately $35,000. Principal Financial Group Inc. acquired a new stake in Poseida Therapeutics during the second quarter worth approximately $35,000. Finally, Virtu Financial LLC acquired a new stake in Poseida Therapeutics during the third quarter worth approximately $37,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.